KRAS and neoplasm: Therefore, we systematically and comprehensively performed the present meta‐analysis to integrate the results of these published studies, aiming to investigate the diagnostic efficiency of cfDNA as a biomarker for KRAS mutations determination compared with the "gold‐standard" tumor tissues and to evaluate the predictive and prognostic value of cfDNA KRAS mutations in CRC patients.